ALK-Abelló A/S/DKr ALK B
07:00
09:00
11:00
12:55
14:55
1D1W1MYTD1Y5YMAX
About ALK-Abelló A/S
ALK-Abelló A/S is a pharmaceutical company engaged in the development and production of allergy immunotherapy products. Based in Hørsholm, Denmark, the company specializes in allergy treatments that include tablets, injections, and drops targeting common allergens such as grass, tree, and ragweed pollen, as well as house dust mites. Established in the early 20th century, ALK-Abelló has expanded its operations to serve markets globally, with a particular focus on Europe and North America. Its strategic advantage lies in its strong research capabilities and a comprehensive portfolio of allergy treatment options. The company's ongoing investment in innovation supports its goal to transform the treatment of allergies worldwide.
Ticker
DKr ALK B
Sector
Primary listing
CSE
Employees
2,759
Headquarters
Horsholm, Denmark
Website
ALK-Abelló A/S Metrics
BasicAdvanced
kr 57bn
44.96
kr 5.78
0.68
kr 1.60
0.62%
Price and volume
Market cap
kr 57bn
Beta
0.68
52-week high
kr 271.40
52-week low
kr 172.40
Average daily volume
202k
Dividend rate
kr 1.60
Financial strength
Current ratio
3.253
Quick ratio
1.916
Long term debt to equity
5.313
Total debt to equity
6.241
Dividend payout ratio (TTM)
27.73%
Interest coverage (TTM)
56.94%
Profitability
EBITDA (TTM)
2,014
Gross margin (TTM)
67.92%
Net profit margin (TTM)
19.51%
Operating margin (TTM)
26.90%
Effective tax rate (TTM)
26.65%
Revenue per employee (TTM)
kr 2,380,000
Management effectiveness
Return on assets (TTM)
12.62%
Return on equity (TTM)
20.91%
Valuation
Price to earnings (TTM)
44.963
Price to revenue (TTM)
8.772
Price to book
8.75
Price to tangible book (TTM)
12.02
Price to free cash flow (TTM)
32.045
Free cash flow yield (TTM)
3.12%
Free cash flow per share (TTM)
8.107
Dividend yield (TTM)
0.62%
Forward dividend yield
0.62%
Growth
Revenue change (TTM)
14.94%
Earnings per share change (TTM)
38.32%
3-year revenue growth (CAGR)
12.65%
10-year revenue growth (CAGR)
9.02%
3-year earnings per share growth (CAGR)
56.41%
10-year earnings per share growth (CAGR)
11.76%
10-year dividend per share growth (CAGR)
20.40%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs